PCOS1
MCID: PLY105
MIFTS: 38

Polycystic Ovary Syndrome 1 (PCOS1)

Categories: Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Polycystic Ovary Syndrome 1

MalaCards integrated aliases for Polycystic Ovary Syndrome 1:

Name: Polycystic Ovary Syndrome 1 56 13
Stein-Leventhal Syndrome 56 74
Polycystic Ovary Syndrome 71
Hyperandrogenemia 56
Pco1; Pco 56
Pcos1 56
Pco1 56
Pcos 56
Pco 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant
probably heterogeneous


HPO:

31
polycystic ovary syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 184700
MedGen 41 C0032460
UMLS 71 C0032460

Summaries for Polycystic Ovary Syndrome 1

MalaCards based summary : Polycystic Ovary Syndrome 1, also known as stein-leventhal syndrome, is related to ovarian cyst and alopecia, androgenetic, 1, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome 1 is PCOS1 (Polycystic Ovary Syndrome 1). The drugs Levonorgestrel and Cetrorelix have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and endothelial, and related phenotypes are abnormality of metabolism/homeostasis and obesity

Wikipedia : 74 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

More information from OMIM: 184700

Related Diseases for Polycystic Ovary Syndrome 1

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
# Related Disease Score Top Affiliating Genes
1 ovarian cyst 11.7
2 alopecia, androgenetic, 1 11.6
3 ovarian hyperstimulation syndrome 11.6
4 cortisone reductase deficiency 11.3
5 cytochrome p450 oxidoreductase deficiency 11.3
6 prediabetes syndrome 11.2
7 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.2
8 hair-an syndrome 11.2
9 hyperandrogenism 11.1
10 anovulation 10.9
11 hyperinsulinism 10.8
12 adenocarcinoma 10.7
13 lipid metabolism disorder 10.7
14 neurofibromatosis, type ii 10.7
15 ovarian disease 10.6
16 endometrial adenocarcinoma 10.6
17 gestational diabetes 10.5
18 amenorrhea 10.5
19 endometrial cancer 10.5
20 breast cancer 10.5
21 cystic teratoma 10.5
22 body mass index quantitative trait locus 1 10.5
23 glucose intolerance 10.5
24 diabetes mellitus, noninsulin-dependent 10.4
25 endometrial hyperplasia 10.4
26 alopecia 10.4
27 rickets 10.4
28 body mass index quantitative trait locus 11 10.3
29 placenta disease 10.3
30 schizophrenia 10.3
31 benign teratoma 10.3
32 duodenal ulcer 10.3
33 epilepsy 10.3
34 multiple endocrine neoplasia 10.3
35 teratoma 10.3
36 pseudohermaphroditism 10.3
37 pituitary adenoma 10.3
38 hypertrichosis 10.3
39 dysgerminoma 10.3
40 mature teratoma 10.3
41 bronchitis 10.3
42 adenoma 10.3
43 muscular dystrophy 10.3
44 aminoaciduria 10.3
45 progressive muscular dystrophy 10.3
46 fatty liver disease 10.3
47 non-alcoholic fatty liver disease 10.3
48 hypothyroidism 10.3
49 sexual disorder 10.3
50 cataract 10.3

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome 1:



Diseases related to Polycystic Ovary Syndrome 1

Symptoms & Phenotypes for Polycystic Ovary Syndrome 1

Human phenotypes related to Polycystic Ovary Syndrome 1:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 obesity 31 HP:0001513
3 enlarged polycystic ovaries 31 HP:0008675
4 hirsutism 31 HP:0001007
5 amenorrhea 31 HP:0000141
6 oligomenorrhea 31 HP:0000876

Symptoms via clinical synopsis from OMIM:

56
Growth:
obesity

Hair:
hirsutism

Misc:
response to bilateral wedge resection of the ovaries
increased frequency of early baldness or excessive hairiness in male first-degree relatives

G U:
enlarged polycystic ovaries
amenorrhea
oligomenorrhea

Endocrine:
no virilization

Lab:
normal 24-hr urinary ketosteroids
elevated dehydroepiandrosteronesulfate
increased 5-alpha-reductase activity in the liver and skin
elevated androstanedione and/or testosterone and luteinizing hormone
low estradiol and follicle-stimulating hormone levels
more

Clinical features from OMIM:

184700

UMLS symptoms related to Polycystic Ovary Syndrome 1:


pelvic pain

Drugs & Therapeutics for Polycystic Ovary Syndrome 1

Drugs for Polycystic Ovary Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
2
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
3
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Alogliptin Approved Phase 4 850649-61-5 11450633
6
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
7
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
8
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
9
Citalopram Approved Phase 4 59729-33-8 2771
10
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Tamoxifen Approved Phase 4 10540-29-1 2733526
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
16
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
17
Liraglutide Approved Phase 4 204656-20-2 44147092
18
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
19
Drospirenone Approved Phase 4 67392-87-4 68873
20
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
21
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
30
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
31
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
32
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
33
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
34
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
35
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
36
leucovorin Approved Phase 4 58-05-9 6006 143
37
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
38
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
39
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
40
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
41
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
42
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
43
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
44
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
45
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
47
Cobalamin Experimental Phase 4 13408-78-1 6857388
48
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
49
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
50 Androgen Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 774)
# Name Status NCT ID Phase Drugs
1 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
2 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
3 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
4 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
5 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
6 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
7 Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial. Unknown status NCT02140398 Phase 4
8 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
9 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
10 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
11 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
12 The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
13 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
14 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
15 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
16 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
17 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
18 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
19 Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients Unknown status NCT01683513 Phase 4 GnRh agonist +1500E hCG
20 Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial Unknown status NCT01665547 Phase 4 l-carnitine
21 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
22 Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages Unknown status NCT01718340 Phase 4 Metformin
23 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
24 Follicular Fluid, Serum Endocrine Profile Following Stimulation With Recombinant Gonadotropins or Highly Purified Human Menopausal Gonadotropin During GnRH-antagonist Protocol Unknown status NCT02992808 Phase 4 recombinant gonadotropins;HP-HMG
25 Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
26 Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome Completed NCT01899430 Phase 4 liraglutide;metformin
27 Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
28 Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS Completed NCT02683226 Phase 4 Vipdomet;Incresync
29 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
30 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
31 Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
32 Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity Completed NCT02909933 Phase 4 liraglutide;metformin and liraglutide
33 A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis. Completed NCT02073929 Phase 4 Liraglutide for 26 weeks;placebo
34 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
35 Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom før og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance) Completed NCT01892254 Phase 4 Metformin;Placebo
36 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
37 A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
38 The Effect of Cipralex in Polycystic Ovary Syndrome Completed NCT01961180 Phase 4 Cipralex;Placebo
39 Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
40 Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
41 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
42 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
43 To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS) Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
44 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
45 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
46 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
47 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
48 Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study Completed NCT01004068 Phase 4 Clomiphene citrate
49 The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study Completed NCT03353948 Phase 4 MET;COMBI
50 The Effects of Oral Isotretinoin in Women With Acne and Polycystic Ovary Syndrome Completed NCT02855138 Phase 4 oral isotretinoin

Search NIH Clinical Center for Polycystic Ovary Syndrome 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Urofollitropin

Genetic Tests for Polycystic Ovary Syndrome 1

Anatomical Context for Polycystic Ovary Syndrome 1

MalaCards organs/tissues related to Polycystic Ovary Syndrome 1:

40
Ovary, Skin, Endothelial, Heart, Liver, Pituitary, Testes

Publications for Polycystic Ovary Syndrome 1

Articles related to Polycystic Ovary Syndrome 1:

(show top 50) (show all 605)
# Title Authors PMID Year
1
Hereditary factors in the Stein-Leventhal syndrome. 61 56
15782458 1968
2
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. 56
21151128 2011
3
Early metabolic derangements in daughters of women with polycystic ovary syndrome. 56
17848407 2007
4
Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. 56
17785364 2007
5
Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. 56
17426092 2007
6
Itchy-dry eye associated with polycystic ovary syndrome. 56
17362862 2007
7
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. 56
16849416 2006
8
Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. 56
16636126 2006
9
Heritability of polycystic ovary syndrome in a Dutch twin-family study. 56
16219714 2006
10
Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. 56
16091490 2005
11
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. 56
15827106 2005
12
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. 56
15507516 2005
13
Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. 56
15181035 2004
14
The prevalence and features of the polycystic ovary syndrome in an unselected population. 56
15181052 2004
15
Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. 56
15126571 2004
16
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. 56
14602801 2003
17
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. 56
12970273 2003
18
Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. 56
11932299 2002
19
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. 56
11836280 2002
20
Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. 56
11344202 2001
21
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. 56
11297583 2001
22
Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. 56
11238505 2001
23
Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. 56
11232039 2001
24
Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. 56
10852468 2000
25
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. 56
10566641 1999
26
A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin. 56
10411866 1999
27
Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. 56
10411917 1999
28
5alpha-reductase activity in women with polycystic ovary syndrome. 56
10404813 1999
29
Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. 56
9920059 1999
30
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. 56
9843997 1998
31
Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. 56
9745406 1998
32
The genetic basis of polycystic ovary syndrome. 56
9455828 1997
33
Leptin concentrations in the polycystic ovary syndrome. 56
9177364 1997
34
Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. 56
9147642 1997
35
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 56
7849715 1994
36
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 56
8334753 1993
37
5 alpha-reductase activity in polycystic ovary syndrome. 56
1968168 1990
38
Familial clustering in the polycystic ovarian syndrome. 56
2777131 1989
39
Familial polycystic ovarian disease. 56
3058473 1988
40
Pathogenesis and treatment of polycystic ovary syndrome. 56
3277057 1988
41
Late-onset adrenal hyperplasia in hirsutism. 56
2989686 1985
42
A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. 56
6633568 1983
43
HLA genotyping in family members and patients with familial polycystic ovarian disease. 56
6833465 1983
44
Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. 56
6977282 1982
45
Androgen production and skin metabolism in hirsutism. 56
925589 1977
46
Polycystic ovarian disease, maturation arrest of spermiogenesis, and Klinefelter's syndrome in siblings of a family with familial hirsutism. 56
803038 1975
47
Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome. 61
31564389 2019
48
Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome). 61
31085787 2019
49
Kisspeptin and Polycystic Ovary Syndrome. 61
31156550 2019
50
Words do matter: a systematic review on how different terminology for the same condition influences management preferences. 61
28698318 2017

Variations for Polycystic Ovary Syndrome 1

Expression for Polycystic Ovary Syndrome 1

Search GEO for disease gene expression data for Polycystic Ovary Syndrome 1.

Pathways for Polycystic Ovary Syndrome 1

GO Terms for Polycystic Ovary Syndrome 1

Sources for Polycystic Ovary Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....